Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRCAT-III: Node-sparing Modified Short-Course Radiation + CAPOX + Tislelizumab in MSS Rectal Cancer
NCT06507371Phase 3Active, not recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in rectal cancer, sponsored by Sir Run-Run Shaw Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06507371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507371.